The Judicial Panel on Multidistrict Litigation has consolidated more than 20 lawsuits against Bristol-Myers Squibb Co. over claims of pathological gambling side effects in patients using the antipsychotic drug Abilify in federal court in Florida. The serious impulse-control problems described in the complaints reportedly stop when the medicine is discontinued. 22 actions pending in 12 districts will be centralized under Chief District Judge M. Casey Rodgers.
Abilify is used to treat patients with schizophrenia, bipolar disorder, and major depressive disorders. Since the drug’s approval through early 2016, there were 184 reports to the FDA and in other medical literature which indicated that Abilify was associated with significant impulse-control problems.
According to court filings, 24 million patients are estimated to have used the drug, which was first introduced to the U.S. over 13 years ago. While Bristol-Myers does make mention of the possibility of compulsive behavior on Abilify’s drug label, the description “does not entirely reflect the nature of the impulse-control risk,” according to the FDA.
As reported by Law360, “By omitting gambling warnings in the U.S., the [plaintiffs] said that the companies have made significantly more revenue from Abilify in the U.S. than in Europe, where regulators have required the warnings on labels.” For example, Bristol-Myers reported that U.S. revenues from the drug’s sales totaled $417 million over three months in 2014, while its non-U.S. revenues for the same period were only $138 million.
The case is In re: Abilify Compulsive Behavior Products Liability Litigation, MDL number 2734, before the U.S. Judicial Panel on Multidistrict Litigation.
Abilify Dangers and Abilify Gambling Risks
In May 2016, the FDA issued a formal warning that the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and also used in generic versions of the drug) has been linked to compulsive urges which can lead to uncontrollable gambling, among other addictions. These rare but serious impulse-control problems reportedly stop when the medicine is discontinued or markedly reduced in dosage.
Lieff Cabraser represents Abilify patients in litigation alleging claims including Strict Liability, Negligent Misrepresentation, and Fraudulent Concealment, and seeks damages for neuropsychiatric, mental, physical, and economic damages, as well as punitive damages. Learn more about the Gambling Addiction Lawsuits.
Contact National Drug Injury Attorneys
Abilify users who suffered extreme and debilitating debt from their Abilify-linked gambling addictions can file lawsuits against Abilify’s manufacturer to recovet their losses and seek help with their ruinous debts and related psychological distress. If you or a family member have suffered losses from compulsive and excessive gambling you think may be linked to Abilify use, we welcome the chance to talk with you. In addition to potentially helping you with your Abilify related losses, learning of your experience can help others suffering from Abilify’s depravations. Please fill out our brief contact form to start the conversation, or call us toll-free at 1 800 541-7358 for help getting recompense for your Abilify gambling compulsions.